Biatain Foam Dressings: Types, IFU & HCPCS

Short answer

Biatain is a family of sterile polyurethane foam wound dressings manufactured by Coloplast for managing moderate-to-heavy wound exudate. Operating under FDA 510(k) clearances and 21 CFR 878.4020, Biatain uses a three-dimensional polymer structure that absorbs drainage vertically and locks moisture in under compression. Variants include non-adhesive, soft-silicone bordered, and antimicrobial silver designs with up to seven-day wear times.

Definition and scope

Notice: This guide provides technical product specifications, regulatory classifications, and supply chain crosswalks for clinical research coordinators, laboratory procurement officers, and clinic inventory specialists. It does not provide individual medical advice, clinical diagnoses, or patient-specific treatment plans.

Biatain is a brand of advanced wound management dressings developed by Coloplast A/S. Built on an open-cell polyurethane foam matrix, standard non-antimicrobial dressings are classified by the FDA as Class I exempt devices under 21 CFR 878.4020 (Product Code NAD, Dressing, Wound, Occlusive). Medicated configurations, including silver-impregnated variants, are regulated under FDA product code FRO (“Dressing, Wound, Drug”) through 510(k) premarket notifications such as K983163, K100218, K120828, K191536, and K231953.

Global Medical Device Nomenclature (GMDN) code 44970 defines the core device as an exudate-absorbent non-gel dressing. Unique Device Identifier (UDI) records in openFDA (DI 05708932761437) confirm that Biatain dressings are sterile, single-use, labeled as not made with natural rubber latex, and require storage away from direct sunlight.

How it works or how it is used in practice

Biatain foam functions through three-dimensional polymer absorption. When placed over an exuding wound, the foam conforms to the wound bed. Rather than dispersing exudate laterally across healthy skin, the polyurethane structure draws drainage vertically into the core, locking fluid under physiological compression. This vertical retention prevents periwound maceration and maintains a moist wound environment.

Manufacturer instructions for use (IFU) establish explicit operational protocols:

• Sizing Margins: The foam pad must extend 1 cm to 2 cm beyond the wound margins onto intact periwound skin to prevent leakage.
• Wear Time Parameters: Dressings may remain in place for up to 7 days, governed by exudate levels. Dressings must be changed when drainage nears 1 cm from the pad edge or if strike-through occurs.
• Bed Preparation: Cleanse the wound with sterile saline or a verified cleanser like puracyn wound cleanser, drying surrounding skin before applying adhesive versions.
• Indications: Indicated for exuding wounds including pressure injuries (Stage II–IV), leg ulcers, diabetic foot ulcers, donor sites, and post-operative incisions.
• Contraindications: Contraindicated for dry wounds, thick dry eschar, or patients with known sensitivities to polyurethane, silicone, or silver. Silver variants must not be combined with oxidizing agents such as hydrogen peroxide or hypochlorites.

Procurement teams evaluate Biatain alongside generic silicone foam wound dressing lines, antimicrobial silver wound care dressings, and bacteria-binding alternatives like a sorbact dressing, verifying listings via openfda medical device datasets.

Types or related concepts

The Biatain product family includes five primary structural architectures designed for specific wound depths and clinical environments:

Product Architecture	Core Material	Adhesive Layer	Target Exudate	Wear Time	Primary HCPCS
Biatain Non-Adhesive	Polyurethane foam pad	None (non-adherent)	Moderate to heavy	Up to 7 days	A6209 / A6210
Biatain Silicone	Polyurethane foam backing	Perforated soft silicone	Moderate to heavy	Up to 7 days	A6212 / A6213
Biatain Silicone Lite	Thin polyurethane foam	Perforated soft silicone	Low to moderate	Up to 7 days	A6212
Biatain Ag / Silicone Ag	Polyurethane foam with ionic silver	Non-adhesive or silicone	Colonized exuding wounds	Up to 7 days	A6209 / A6212
Biatain Fiber Ag	CMC and alginate gelling fiber	Non-bordered ribbon/pad	Cavity / heavy drainage	Up to 7 days	A6196 / A6199

Where it matters for labs, clinics or supply decisions

Dressing standardization impacts multi-center clinical trials, Medicare outpatient reimbursement, and hospital inventory control.

Clinical Research Protocols

In dermatological clinical trials, standardizing dressing regimens eliminates confounding variables. Biatain’s predictable fluid retention maintains uniform wound hydration without chemical residue, ensuring consistent photographic assessment and endpoint validity across research sites.

Reimbursement and HCPCS Coding

Under CMS DME MAC Local Coverage Determination (LCD) L33831 and Policy Article A54563, foam dressings are covered for wounds with moderate to heavy exudate resulting from surgery or documented debridement. Medicare covers primary foam dressings up to a change frequency of 3 times per week, billed by packaged pad dimensions:

HCPCS Code	CMS Descriptor Category	Pad Area Tier	Medicare Utilization Limit
A6209	Foam dressing, cover, sterile, without adhesive border	Pad ≤ 16 sq. in.	Up to 3 per week
A6210	Foam dressing, cover, sterile, without adhesive border	Pad 16 to 48 sq. in.	Up to 3 per week
A6211	Foam dressing, cover, sterile, without adhesive border	Pad > 48 sq. in.	Up to 3 per week
A6212	Foam dressing, cover, sterile, with adhesive border	Pad ≤ 16 sq. in.	Up to 3 per week
A6213	Foam dressing, cover, sterile, with adhesive border	Pad 16 to 48 sq. in.	Up to 3 per week
A6214	Foam dressing, cover, sterile, with adhesive border	Pad > 48 sq. in.	Up to 3 per week

Procurement and Storage Guidelines

Biatain dressings are supplied in boxes of 10 or 20 sterile individual peel-pouches. Polyurethane degrades under ultraviolet radiation; store boxes away from direct sunlight at 15°C to 30°C (59°F to 86°F). Antimicrobial silver configurations have shorter shelf lives than standard foams; clinics should maintain 30-day inventory cycles to prevent formulary expiration.

Common misunderstandings

• Misunderstanding: Foam dressings can be placed on dry, necrotic tissue.
  Correction: Polyurethane foams require wound moisture to operate. Placing foam on dry eschar can cause the dressing to adhere to tissue, causing traumatic skin tearing during removal. Dry wounds require rehydration with hydrogels before foam use.
• Misunderstanding: Antimicrobial silver foam (Biatain Ag) is suitable for routine non-infected wound care.
  Correction: Silver dressings are indicated only for wounds with critical bacterial colonization or delayed healing. Clinical guidelines recommend re-evaluating silver use after 14 days and stepping down to standard foam once bioburden is controlled.
• Misunderstanding: Facilities should bill CMS based on trimmed dressing size.
  Correction: Under CMS Policy Article A54563, dressings must be billed according to the original manufactured dimensions supplied in the box, not the cut size used on the wound.

FAQ

What is the difference between Biatain Silicone and Biatain Non-Adhesive?

Biatain Silicone includes a soft silicone adhesive border that sticks gently to intact skin for atraumatic removal without secondary tape. Biatain Non-Adhesive is an unbordered foam pad intended for fragile skin or application beneath compression bandaging.

How long can a Biatain dressing remain on a wound?

Biatain can remain in place for up to 7 days, but must be replaced whenever exudate reaches within 1 cm of the pad margin or if leakage occurs.

What HCPCS codes apply to Biatain foam dressings?

Non-bordered dressings map to A6209 (≤ 16 sq. in.), A6210 (16 to 48 sq. in.), and A6211 (> 48 sq. in.). Bordered silicone models map to A6212 (≤ 16 sq. in.), A6213 (16 to 48 sq. in.), and A6214 (> 48 sq. in.).

Are Biatain dressings latex-free?

Yes. FDA AccessGUDID listings and manufacturer labeling confirm Biatain dressings are not made with natural rubber latex.

Sources

• United States Food and Drug Administration (FDA). 510(k) Premarket Notifications K983163, K100218, K120828, K191536, K231953 (Coloplast Biatain). Accessed November 9, 2026. https://api.fda.gov/device/510k.json
• United States Food and Drug Administration (FDA). AccessGUDID Database: Biatain Silicone Fit (DI 05708932761437, 21 CFR 878.4020, GMDN 44970). Accessed November 9, 2026. https://api.fda.gov/device/udi.json
• Coloplast A/S. Biatain Foam, Biatain Silicone, and Biatain Ag Instructions for Use (IFU). Accessed November 9, 2026. https://www.coloplast.us/
• Centers for Medicare and Medicaid Services (CMS). DME MAC LCD L33831 and Policy Article A54563: Surgical Dressings. Accessed November 9, 2026. https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=54563